Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 8, 2026

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

Romidepsin for peripheral T-cell lymphoma.

Amit Khot1, Michael Dickinson, H Miles Prince

  • 1Peter MacCallum Cancer Centre, Division of Cancer Medicine, Locked Bag 1, A'Beckett St., VIC 8006, Australia. amit.khot@petermac.org

Expert Review of Hematology
|September 3, 2013
PubMed
Summary

Romidepsin, a novel histone deacetylase inhibitor, shows significant activity and tolerability in Peripheral T-cell lymphoma (PTCL) patients. This finding supports exploring romidepsin in combination therapies for improved T-cell lymphoma treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durable response to salvage gilteritinib, allogeneic stem cell rescue and maintenance therapy in relapsed AML with a <i>FLT3</i> N676K variant.

Leukemia & lymphoma·2026
Same author

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Future oncology (London, England)·2026
Same author

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Internal medicine journal·2026
Same author

Early-Life Exposures and Risk of Multiple Myeloma: A Population-Based Case-Control Study in Australia.

International journal of cancer·2026
Same author

Diet and risk of multiple myeloma: findings from a case-control study.

The British journal of nutrition·2026
Same author

Innovative approaches for managing relapsed or refractory peripheral T-cell lymphoma.

Expert opinion on pharmacotherapy·2026

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous cancer with poor outcomes using conventional chemotherapy.
  • There is a critical need for novel therapeutic strategies, including dose-intensification and agents with new mechanisms of action, to improve patient survival.
  • Histone deacetylase (HDAC) inhibitors represent a promising class of drugs targeting epigenetic modifications in cancer.

Purpose of the Study:

  • To review the efficacy and tolerability of romidepsin, a histone deacetylase inhibitor, in patients with T-cell lymphoma.
  • To evaluate the potential of romidepsin as a single agent and as a basis for combination therapies.
  • To demonstrate the proof-of-principle for HDAC inhibitors in treating T-cell lymphomas.

Main Methods:

More Related Videos

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

Related Experiment Videos

Last Updated: May 8, 2026

Expansion of Human Peripheral Blood &gamma;&delta; T Cells using Zoledronate
13:08

Expansion of Human Peripheral Blood γδ T Cells using Zoledronate

Published on: September 9, 2011

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment
11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

  • Review of two large Phase II clinical trials involving romidepsin treatment for T-cell lymphoma.
  • Analysis of clinical data focusing on treatment activity, response rates, and adverse events.
  • Assessment of romidepsin's mechanism of action as a histone deacetylase inhibitor.

Main Results:

  • Romidepsin demonstrated considerable clinical activity in patients with T-cell lymphoma.
  • The drug was generally well-tolerated, indicating a favorable safety profile.
  • Phase II trial results provide a strong foundation for further clinical investigation.

Conclusions:

  • Single-agent romidepsin shows promising activity and tolerability in T-cell lymphoma.
  • These findings support the development of romidepsin-based combination strategies.
  • Romidepsin validates the therapeutic potential of histone deacetylase inhibitors in T-cell lymphoma treatment.